8-K: Immunome Announces Third Quarter 2024 Financial Results and Provides Business Update

Immunome reported its third quarter 2024 financial results, highlighting progress in its clinical pipeline and a cash runway extending into 2026.

Summary

• Immunome announced its financial results for the third quarter ended September 30, 2024, and provided an update on its business activities.
• The company's cash, cash equivalents, and marketable securities totaled $240.1 million as of September 30, 2024.
• Immunome's current cash runway is expected to extend into 2026.
• Research and development expenses for the quarter were $37.2 million, including $1.8 million in stock-based compensation.
• In-process research and development expenses were $6.7 million for the quarter, related to business development activity.
• General and administrative expenses totaled $9.5 million, including $3.1 million in stock-based compensation.
• The company reported a net loss of $47.1 million for the quarter.
• Topline data for the RINGSIDE Part B trial of AL102 is expected in the second half of 2025.
• IND submissions for IM-1021 and IM-3050 are on track for the first quarter of 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong cash position, extended runway, and progress in the clinical pipeline. However, the significant net loss and R&D expenses temper the overall outlook.

Positives

• Immunome has a strong cash position of $240.1 million.
• The company's cash runway is expected to last into 2026.
• The Phase 3 RINGSIDE Part B study of AL102 has completed enrollment.
• IND submissions for IM-1021 and IM-3050 are on track for the first quarter of 2025.
• The company is actively advancing its pipeline of targeted oncology therapies.

Negatives

• Immunome reported a net loss of $47.1 million for the third quarter of 2024.
• Research and development expenses were significant at $37.2 million for the quarter.
• General and administrative expenses were $9.5 million for the quarter.

Risks

• The company's future results may differ materially from forward-looking statements due to various factors.
• There is a risk that regulatory approvals for Immunome's programs and product candidates may be delayed or not obtained.
• Pre-clinical data may not be predictive of clinical data.
• Product candidates may fail to achieve their intended endpoints.
• There are uncertainties related to Immunome's capital requirements and expected cash runway.

Future Outlook

Immunome expects to report topline data for the RINGSIDE Part B trial in the second half of 2025 and anticipates submitting INDs for IM-1021 and IM-3050 in the first quarter of 2025. The company's cash runway is expected to extend into 2026.

Management Comments

• Immunome continues to advance its pipeline, said Clay B. Siegall, Ph.D., President and Chief Executive Officer.
• Our discovery team is focused on discovering ADCs that effectively pursue the novel targets we believe will define the next generation of transformative cancer therapies.

Industry Context

Immunome is operating in the competitive biotechnology sector, focusing on targeted oncology therapies, particularly antibody-drug conjugates (ADCs). The company's pipeline includes a Phase 3 trial for AL102 and IND submissions for IM-1021 and IM-3050, placing it among companies developing novel cancer treatments.

Comparison to Industry Standards

• Immunome's cash position of $240.1 million is relatively strong for a clinical-stage biotech company, providing a runway into 2026, which is comparable to other companies at a similar stage.
• The R&D expenses of $37.2 million for the quarter are typical for a company advancing multiple clinical programs, similar to companies like Arcus Biosciences or Iovance Biotherapeutics.
• The net loss of $47.1 million is also within the expected range for a company in this phase of development, as most biotech companies are not profitable until they have commercialized products, similar to companies like Mirati Therapeutics or Deciphera Pharmaceuticals.
• The focus on ADCs and novel targets aligns with current industry trends in oncology drug development, similar to companies like Seagen and ADC Therapeutics.

Stakeholder Impact

• Shareholders will be interested in the company's financial performance and clinical progress.
• Employees will be impacted by the company's continued operations and development activities.
• Patients may benefit from the development of new cancer therapies.
• Creditors will be interested in the company's financial stability and cash runway.

Next Steps

• Immunome will continue to advance its clinical pipeline.
• The company expects to report topline data for the RINGSIDE Part B trial in the second half of 2025.
• Immunome anticipates submitting INDs for IM-1021 and IM-3050 in the first quarter of 2025.
• The company will continue manufacturing and pharmacology work to support a new drug application filing for AL102.

Key Dates

Keywords

oncology, biotechnology, targeted therapies, antibody-drug conjugates, clinical trials, RINGSIDE, AL102, IM-1021, IM-3050, IND submission, financial results, cash runway